AbbVie Puts Potential $713M on the Line for OSE’s Inflammation Antibody

AbbVie on Wednesday entered into a strategic partnership with OSE Immunotherapeutics to advance the French biotech’s early-stage monoclonal antibody OSE-230 as a treatment for chronic and severe inflammation.